Active, not recruitingPhase 2NCT05090384
Pediatric GVHD Low Risk Steroid Taper Trial
Studying Graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- John Levine
- Principal Investigator
- John E Levine, MD, MSIcahn School of Medicine at Mount Sinai
- Intervention
- Prednisone(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2022 – 2026
Study locations (11)
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Boston Children's Hospital Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States
- Medical College of Wisconsin / Children's Wisconsin, Milwaukee, Wisconsin, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05090384 on ClinicalTrials.govOther trials for Graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07166848Electrostimulation Study for Ocular Graft vs. Host DiseaseZhonghui K. Luo, MD, PhD
- RECRUITINGPHASE2NCT07246031BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell TransplantationBioPhoenix Co., Ltd.
- RECRUITINGNANCT07184853Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT07118254A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)Lubris Bio Pty Ltd
- RECRUITINGPHASE4NCT06824103Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07047456Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBTAnhui Provincial Hospital
- RECRUITINGPHASE2NCT06799195Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationUniversity of Nebraska
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07162688Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.Fujian Medical University